Wegovy and the Risk of Blindness: What the Evidence Shows

Step 1: What the research actually found

The concern about Wegovy and vision loss centres on a condition called non-arteritic anterior ischaemic optic neuropathy, or NAION. It occurs when blood flow to the front of the optic nerve is suddenly interrupted, causing painless but potentially permanent vision loss, often in one eye and often noticed on waking. It is uncommon in the general population.

A retrospective cohort study published in JAMA Ophthalmology in 2024 examined records from a large US database and found that people using semaglutide had a higher rate of NAION diagnoses than people using other weight-loss or diabetes medicines. In the obesity group, the incidence of NAION was 8.9 per 10,000 person-years in semaglutide users compared with 1.8 per 10,000 in non-users. Those numbers are small in absolute terms, but the relative difference caught the attention of regulators and researchers. It is worth being clear about what the study did not do: it could not rule out confounding factors, it did not establish that semaglutide caused the cases, and it was not a clinical trial designed to test causation.

Regulators including the MHRA and the European Medicines Agency have reviewed the signal. As of mid-2026, NAION is listed under the Wegovy product information as a potential concern, and ongoing pharmacovigilance is active. No regulatory body has concluded that semaglutide causes NAION; equally, no body has dismissed the signal. That is where the science stands.

Step 2: Who may face a higher background risk

NAION does not arise from nowhere. Certain pre-existing factors raise a person's baseline susceptibility, and these matter when weighing up treatment. A "disc at risk" optic nerve anatomy (a structural feature visible on eye examination), a previous NAION episode in the other eye, high blood pressure, obstructive sleep apnoea, diabetes, and high cholesterol are all recognised risk factors for NAION independent of any medicine.

This is why the overlap with the population likely to be considered for Wegovy is clinically interesting: people with obesity often have one or more of these conditions. Separating a medicine's contribution from the background risk of the population taking it is genuinely difficult, and that difficulty is part of why researchers are cautious about drawing firm conclusions.

If you have a history of optic nerve problems, glaucoma, or a previous episode of sudden vision change, make sure your prescriber knows. Our Wegovy treatment overview sets out the full picture of how the clinical assessment works, and the broader Wegovy risks page covers other areas of the safety profile. A thorough history, including eye health, is part of every consultation.

Step 3: When to get medical help and what to report

The critical practical point is this: sudden vision changes are never something to wait on. If you are taking Wegovy and notice any of the following, contact an eye casualty unit or call 999 without delay.

Symptoms that need same-day urgent assessment include sudden blurring or loss of vision in one or both eyes, a dark patch or shadow that has appeared in your field of view, or any visual disturbance that came on quickly and without explanation. NAION typically presents on waking, painlessly, so the absence of pain should not reassure you that something is not happening.

For symptoms that are less acute but still new or worrying, contact your prescriber, GP, or optometrist promptly rather than waiting for a scheduled review. The full Wegovy side effects guide covers the wider range of things to watch for during treatment, including gastrointestinal symptoms and fatigue, which you can read about on the Wegovy and tiredness page.

Any suspected adverse effect can be reported to the MHRA using the Yellow Card scheme. You do not need a clinical background to report; patients and carers submit reports, and they are genuinely useful to regulators tracking signals like this one. If you have concerns about a specific symptom, our support team is available seven days a week.

Putting the risk in context alongside Wegovy's established benefits

Obesity is itself a significant driver of cardiovascular disease, type 2 diabetes, sleep apnoea, and several other conditions that affect quality and length of life. Wegovy has robust evidence of meaningful average weight reduction from the STEP 1 trial, published in the New England Journal of Medicine, and a separate cardiovascular outcomes trial showed a reduction in major cardiovascular events in eligible adults. The question a prescriber works through is not whether Wegovy carries any risk — every medicine does — but whether the risks are outweighed by the expected benefits for this particular person at this point in their health.

The NAION signal does not change that calculus for most people, but it does add a consideration for those with relevant eye history. The safety profile for people with high blood pressure is a related question our prescribers discuss regularly, since hypertension sits in both the NAION risk-factor list and the Wegovy-indicated-comorbidity list. For a grounded sense of overall safety evidence, the risk of Wegovy overview is a good place to start.

Our prescribers at nume discuss suitability, individual risk factors, and side-effect concerns as a proper part of every consultation, not as a box-tick. If questions about your eye health or other conditions are part of why you have not yet started treatment, that conversation is exactly what the free consultation is for.